Literature DB >> 24737507

Investigation of a PAX6 gene mutation in a Malaysian family with congenital aniridia.

P C Lee1, H H Lam2, S A Ghani2, V Subrayan3, K H Chua4.   

Abstract

Mutations in the PAX6 gene that cause aniridia have been identified in various ethnicities but not in the Malaysian population. Therefore, the objective of this study was to investigate the PAX6 mutation in a Malaysian family with congenital aniridia. In this study, a complete ophthalmic examination was performed on a Dusun ethnic family with aniridia. Genomic DNA was extracted from the peripheral blood of the subjects and screened for the PAX6 gene mutation using polymerase chain reaction amplification high-resolution melting curve analysis (PCR-HRM) followed by confirmation via direct DNA sequencing. A heterozygous G deletion (c.857delG) in exon 7 causing a frame shift in PAX6 was identified in all affected family members. Genotype-phenotype correlation analysis revealed congenital cataract and all affected family members showed a similar spectrum of aniridia with no phenotypic variability but with differences in severity that were age-dependent. In summary, by using a PCR-HRM approach, this study is the first to report a PAX6 mutation in a Malaysian family. This mutation is the cause of the aniridia spectra observed in this family and of congenital cataract.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24737507     DOI: 10.4238/2014.March.24.15

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  2 in total

1.  Bilateral aniridia and congenital ureteral valve: Role of genetic testing.

Authors:  Lisa B E Shields; Dennis S Peppas; Eran Rosenberg
Journal:  Mol Genet Genomic Med       Date:  2020-02-14       Impact factor: 2.183

2.  A novel 4.25 kb heterozygous deletion in PAX6 in a Chinese Han family with congenital aniridia combined with cataract and nystagmus.

Authors:  Tianwei Qian; Chong Chen; Caihua Li; Qiaoyun Gong; Kun Liu; Gao Wang; Isabelle Schrauwen; Xun Xu
Journal:  BMC Ophthalmol       Date:  2021-10-05       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.